Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone
- PMID: 19815834
- PMCID: PMC2791948
- DOI: 10.3324/haematol.2009.009118
Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone
Comment on
-
Combined therapy with deferiprone and desferrioxamine in thalassemia major.Haematologica. 2005 Oct;90(10):1309-14. Haematologica. 2005. PMID: 16219566
-
A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major.Haematologica. 2007 Dec;92(12):1599-606. doi: 10.3324/haematol.11414. Haematologica. 2007. PMID: 18055982 Clinical Trial.
References
-
- Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000;355:2051–2. - PubMed
-
- Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89:1187–93. - PubMed
-
- Telfer P, Coen PG, Christou S, Hadjigavriel M, Kolnakou A, Pangalou E, et al. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980–2004. Haematologica. 2006;91:1187–92. - PubMed
-
- Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol. 1998;103:361–4. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
